Summit's High-Profile Drug Flops And Shares Crash – Investor's Business Daily

Business News

  1. Summit’s High-Profile Drug Flops And Shares Crash  Investor’s Business Daily
  2. Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster  statnews.com
  3. Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332  Yahoo Finance
  4. WCLC25: Summit’s Keytruda challenger faces more questions over regional data differences  FirstWord Pharma
  5. Summit’s global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend  Fierce Pharma

Source: Business News

/by